Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or ...

Vallourec, a world leader in premium tubular solutions, announces today its results for the second quarter 2025. The Board of Directors of Vallourec SA, meeting on July 24 th 2025, approved the ...

RENEWAL OF THE TERM OF THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF VALLOUREC Meudon (France), on July 24th, 2025 – The Board ...